Aptamer-Mediated Delivery of Splice-Switching Oligonucleotides to the Nuclei of Cancer Cells

Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Nucleic acid therapeutics 06/2012; 22(3):187-95. DOI: 10.1089/nat.2012.0347
Source: PubMed


To reduce the adverse effects of cancer therapies and increase their efficacy, new delivery agents that specifically target cancer cells are needed. We and others have shown that aptamers can selectively deliver therapeutic oligonucleotides to the endosome and cytoplasm of cancer cells that express a particular cell surface receptor. Identifying a single aptamer that can internalize into many different cancer cell-types would increase the utility of aptamer-mediated delivery of therapeutic agents. We investigated the ability of the nucleolin aptamer (AS1411) to internalize into multiple cancer cell types and observed that it internalizes into a wide variety of cancer cells and migrates to the nucleus. To determine if the aptamer could be utilized to deliver therapeutic oligonucleotides to modulate events in the nucleus, we evaluated the ability of the aptamer to deliver splice-switching oligonucleotides. We observed that aptamer-splice-switching oligonucleotide chimeras can alter splicing in the nuclei of treated cells and are effective at lower doses than the splice switching oligonucleotides alone. Our results suggest that aptamers can be utilized to deliver oligonucleotides to the nucleus of a wide variety of cancer cells to modulate nuclear events such as RNA splicing.

Download full-text


Available from: Elizabeth Pratico
    • "Nucleolin is a nuclear protein which could be overexpressed on plasma membrane of certain cancer cells such as lung and pancreatic cancers [23] [24] [25]. So, after the internalization of PA-Dau-AuNPs complex into Molt-4 cells by sgc8c aptamer, the complex could be internalized into the nuclei of cancer cells through AS1411 aptamer [26], leading to enhancement of the therapeutic efficacy of Dau. Also, in this study AuNPs were used as carriers for delivery of Dau and polyvalent aptamers to increase the therapeutic efficacy of the targeted drug delivery system because of their high capacity for loading of drug and polyvalent aptamers. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical use of daunorubicin (Dau) in treatment of leukemia has been restricted because of its cardiotoxicity. Targeted delivery of anticancer drugs could decrease their off-target effects and enhance their efficacy. In this study a modified polyvalent aptamers (PA)-Daunorubicin (Dau)-Gold nanoparticles (AuNPs) complex was designed and its efficacy was assessed in Molt-4 cells (human acute lymphoblastic leukemia T-cell, target). Dau was efficiently loaded (10.5 µM) onto 1 mL of PA-modified AuNPs. Dau was released from the PA-Dau-AuNPs complex in a pH-sensitive manner (faster release at pH 5.5). The results of flow cytometry analysis indicated that the PA-Dau-AuNPs complex was efficiently internalized into target cells, but not into nontarget cells. The results of MTT assay were consistent with the internalization data. PA-Dau-AuNPs complex had less cytotoxicity in U266 cells compared to Dau alone and even Apt-Dau-AuNPs complex. The PA-Dau-AuNPs complex had more cytotoxicity in Molt-4 cells compared to Dau alone and even Apt-Dau-AuNPs complex. Cytotoxicity of PA-Dau-AuNPs complex was effectively antagonized using antisense of polyvalent aptamers. In conclusion, the designed drug delivery system inherited properties of efficient drug loading, tumor targeting, pH-dependent drug release and controllable delivery of Dau to tumor cells.
    No preview · Article · Feb 2016 · Materials Science and Engineering C
  • Source
    • "Nucleolin is a phosphoprotein overexpressed in cytoplasm and on plasma membrane of the metastatic cells, and not the normal cells. AS1411 enters many different cancer cell-types via nucleolin-mediated endocytosis[12] [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A simple but highly sensitive colorimetric method was developed to detect cancer cells based on aptamer-cell interaction. Cancer cells were able to capture nucleolin aptamers (AS 1411) through affinity interaction between AS 1411 and nucleolin receptors that are over expressed in cancer cells, The specific binding of AS 1411 to the target cells triggered the removal of aptamers from the solution. Therefore no aptamer remained in the solution to hybridize with complementary ssDNA-AuNP probes as a result the solution color is red. In the absence of target cells or the presence of normal cells, ssDNA-AuNP probes and aptamers were coexisted in solution and the aptamers assembled DNA-AuNPs, produced a purple solution. UV-vis spectrometry demonstrated that this hybridization-based method exhibited selective colorimetric responses to the presence or absence of target cells, which is detectable with naked eye. The linear response for MCF-7 cells in a concentration range from 10 to 10(5) cells was obtained with a detection limit of 10 cells. The proposed method could be extended to detect other cells and showed potential applications in cancer cell detection and early cancer diagnosis.
    Full-text · Article · Nov 2015 · Analytica chimica acta
  • Source
    • "In 2012, Sullenger and coworkers71 used G-quadruplex-forming AS1411 DNA aptamers to deliver SSOs into the nuclei of cancer cells (Figure 1d). As a form of antisense technology, single-stranded RNA oligonucleotides are designed to bind to a splice site or splicing enhancers, thereby blocking access to the endogenous splicing machinery and resulting in an alternate version of mature mRNA for translation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: One hundred years ago, Dr. Paul Ehrlich popularized the "magic bullet" concept for cancer therapy in which an ideal therapeutic agent would only kill the specific tumor cells it targeted. Since then, "targeted therapy" that specifically targets the molecular defects responsible for a patient's condition has become a long-standing goal for treating human disease. However, safe and efficient drug delivery during the treatment of cancer and infectious disease remains a major challenge for clinical translation and the development of new therapies. The advent of SELEX technology has inspired many groundbreaking studies that successfully adapted cell-specific aptamers for targeted delivery of active drug substances in both in vitro and in vivo models. By covalently linking or physically functionalizing the cell-specific aptamers with therapeutic agents, such as siRNA, microRNA, chemotherapeutics or toxins, or delivery vehicles, such as organic or inorganic nanocarriers, the targeted cells and tissues can be specifically recognized and the therapeutic compounds internalized, thereby improving the local concentration of the drug and its therapeutic efficacy. Currently, many cell-type-specific aptamers have been developed that can target distinct diseases or tissues in a cell-type-specific manner. In this review, we discuss recent advances in the use of cell-specific aptamers for targeted disease therapy, as well as conjugation strategies and challenges.
    Full-text · Article · Jun 2014 · Molecular Therapy - Nucleic Acids
Show more